The US Food and Drug Administration (FDA) yesterday approved an inhalation spray version of tiotropium bromide (Spiriva Respimat, Boehringer Ingelheim) for maintenance treatment of chronic obstructive ...

SPIRIVA RESPIMAT Inhalation Spray is now available by prescription through retail pharmacies across the United States for the long-term, once-daily maintenance treatment of bronchospasm associated ...

Boehringer Ingelheim announced that Spiriva Respimat (tiotropium bromide) is now available for the long-term maintenance treatment of asthma in patients ages ≥12 years. Boehringer Ingelheim announced ...

Tiotropium as Asthma Add-On Treatment Shows Promise Boehringer Ingelheim announced that the Food and Drug Administration (FDA) has approved Spiriva Respimat (tiotropium bromide) inhalation spray for ...

Please provide your email address to receive an email when new articles are posted on . We were unable to process your request. Please try again later. If you continue to have this issue please ...

RIDGEFIELD, Conn., Oct. 11, 2018 /PRNewswire/ -- Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) approved new labeling for Stiolto Respimat (tiotropium bromide & ...

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced the publication of new data from the Phase IIIb OTEMTO ® 1&2 trials (NCT01964352 ...

Spiolto® Respimat® is built on tiotropium, the active ingredient in Spiriva®, enhanced by olodaterol Spiolto® Respimat® provides significant improvements in lung function, COPD symptoms, quality of ...

Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Once-daily tiotropium bromide as an add-on to inhaled corticosteroid therapy demonstrated ...

RIDGEFIELD, Conn., May 26, 2015 -- Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved once-daily STIOLTO™ RESPIMAT® (tiotropium bromide and olodaterol) ...

OTEMTO ® 1&2 post-hoc analysis reinforces quality of life benefits provided by Spiolto ® Respimat ® right from the initial stage when patients first need maintenance therapy * Head-to-head ENERGITO ® ...

DUBLIN--(BUSINESS WIRE)--The "Spiriva" report has been added to ResearchAndMarkets.com's offering. Spiriva (tiotropium; Boehringer Ingelheim) is a long-acting muscarinic antagonist (LAMA) approved for ...